NCT06492330 - Efficacy and Safety of CS0159 Combined With Semaglutide in MASH Patients With Obesity and T2DM | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 19, 2024

Primary Completion Date

February 28, 2025

Study Completion Date

April 22, 2025

Conditions

Metabolic Dysfunction-Associated Steatohepatitis (MASH)ObesityDiabetes Mellitus, Type 2

Interventions

DRUG

CS0159

The intervention will include a 2-week screening period, a 16-week treatment period, and a 4-week follow-up period. Efficacy and safety evaluations will be conducted after the end of the treatment. During the 16-week treatment period, subjects will receive 4mg CS0159 (oral, once daily) + 0.5mg Semaglutide (subcutaneous injection, once weekly).

DRUG

CS0159 placebo

The intervention will include a 2-week screening period, a 16-week treatment period, and a 4-week follow-up period. Efficacy and safety evaluations will be conducted after the end of the treatment. During the 16-week treatment period, subjects will receive CS0159 placebo (oral, once daily) + 0.5mg Semaglutide (subcutaneous injection, once weekly).

Trial Locations (1)

200025

Dep.endocrinology of Shanghai Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors

lead

Shanghai Jiao Tong University School of Medicine

OTHER